First Trial of CRISPR-Edited T cells in Lung Cancer.
First Trial of CRISPR-Edited T cells in Lung Cancer.
Trends Mol Med. 2020 Jun 12;:
Authors: Lacey SF, Fraietta JA
Abstract
The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy.
PMID: 32536469 [PubMed - as supplied by publisher]
Source: Trends in Molecular Medicine - Category: Molecular Biology Authors: Lacey SF, Fraietta JA Tags: Trends Mol Med Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Molecular Biology | Non-Small Cell Lung Cancer | Science